Nervgen Pharma Corp Stock Current Asset
NGEN Stock | CAD 2.88 0.01 0.35% |
NervGen Pharma Corp fundamentals help investors to digest information that contributes to NervGen Pharma's financial success or failures. It also enables traders to predict the movement of NervGen Stock. The fundamental analysis module provides a way to measure NervGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NervGen Pharma stock.
Non Current Assets Total is likely to drop to about 555.8 K in 2024. Total Current Assets is likely to drop to about 10.7 M in 2024. NervGen | Current Asset |
NervGen Pharma Corp Company Current Asset Analysis
NervGen Pharma's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
NervGen Current Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for NervGen Pharma is extremely important. It helps to project a fair market value of NervGen Stock properly, considering its historical fundamentals such as Current Asset. Since NervGen Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NervGen Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NervGen Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition |
NervGen Total Assets
Total Assets |
|
In accordance with the recently published financial statements, NervGen Pharma Corp has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all Canada stocks is 100.0% higher than that of the company.
NervGen Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of NervGen Pharma from analyzing NervGen Pharma's financial statements. These drivers represent accounts that assess NervGen Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NervGen Pharma's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Enterprise Value | 44.9M | 46.7M | 66.0M | 90.3M | 81.3M | 47.2M |
NervGen Fundamentals
Return On Equity | -2.3 | ||||
Return On Asset | -0.53 | ||||
Current Valuation | 181.61 M | ||||
Shares Outstanding | 70.31 M | ||||
Shares Owned By Insiders | 22.91 % | ||||
Shares Owned By Institutions | 0.06 % | ||||
Number Of Shares Shorted | 199.54 K | ||||
Price To Book | 22.06 X | ||||
EBITDA | (19.24 M) | ||||
Net Income | (22.38 M) | ||||
Cash And Equivalents | 8.27 M | ||||
Cash Per Share | 0.30 X | ||||
Total Debt | 15.25 M | ||||
Current Ratio | 25.72 X | ||||
Book Value Per Share | (0.03) X | ||||
Cash Flow From Operations | (11.3 M) | ||||
Short Ratio | 4.77 X | ||||
Earnings Per Share | (0.38) X | ||||
Target Price | 4.5 | ||||
Beta | 1.35 | ||||
Market Capitalization | 202.49 M | ||||
Total Asset | 13.24 M | ||||
Retained Earnings | (78.15 M) | ||||
Working Capital | (2.62 M) | ||||
Net Asset | 13.24 M |
About NervGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.